Engineered nanoparticles built around indocyanine green, a fluorescent dye already approved for clinical use, could sharpen how surgeons see and remove tumors during operations. A study in the journal ...

Mesothelin-targeted CAR-NKT cells leveraged three recognition mechanisms, potentially limiting antigen escape and immunoediting compared with single-pathway CAR-T constructs. Complete tumor ...

Study Carried Out by Center for Research and Advanced Studies of the IPN and the Siglo XXI National Medical Center Show Advantages of Oral Administration of CBD to Reduce Levels of Neuronal Death in ...

A preclinical study led by the Smidt Heart Institute at Cedars-Sinai challenges the assumption that blocking the NCX1 protein, which regulates calcium levels in cells, is more effective than ...

(Nasdaq: ELAB) (“PMGC” or the “Company”) today announced the initiation of a preclinical study for EL-32, an engineered probiotic candidate being developed by its wholly owned subsidiary, NorthStrive ...

VANCOUVER, Washington, Feb. 01, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for ...

Pancreatic malignancies remain some of the most challenging cancers to treat. Experts anticipate over 52,000 pancreatic cancer-related deaths this year. Sadly, the five-year survival rate for ...

BITS Pilani's new nanomedicine gel shows promising preclinical results for rheumatoid arthritis treatment, enhancing drug delivery and reducing inflammation.

The study demonstrated that lanifibranor improved Portal Hypertension (PH) in mouse models of fibrotic PH and prehepatic non-fibrotic PH Lanifibranor was observed to decrease portal pressure by ...

Our faculty-led laboratories investigate a broad range of conditions spanning kidney stone disease, endourologic disorders, and urologic cancers. Research within the department encompasses all stages ...

LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases ...